Corporate ActionApr 30, 2026, 05:17 PM
VALN Completes €84M Reserved Offering
AI Summary
Valneva SE successfully completed an €84 million reserved offering, which includes €37 million expected upon closing and up to €47 million if all warrants are exercised. The closing is anticipated on May 5, 2026. The company intends to use the net proceeds to advance its vaccine pipeline, maximize growth of its commercial business, and for working capital and general corporate purposes, with an equal allocation between these two objectives. The offering was led by existing investor Frazier Life Sciences, with participation from new and existing investors.
Key Highlights
- VALN completed €84 million reserved offering.
- €37 million expected upon closing on May 5, 2026.
- Up to €47 million if all warrants are exercised.
- Investors purchased 15,893,817 ABSA units.
- ABSA price set at €2.33 per unit.
- Proceeds to advance vaccine pipeline and grow commercial business.
- Proceeds also for working capital and general corporate purposes.